Home >  News >  Industry >  Pharma News >  Zydus Wellness...

Zydus Wellness proactively looking for acquisitions; to enter new overseas markets

Zydus Wellness has integrated the business of Heinz, including a portfolio of popular brands Complan, Glucon-D and Nycil, which it had acquired in a Rs 4,595-crore acquisition, the annual report said.;

By - Ruchika Sharma
Published On 2022-07-09 04:30 GMT   |   Update On 2022-07-09 04:30 GMT
Advertisement

New Delhi: Ahmedabad-based consumer goods company Zydus Wellness, which owns iconic brands such as Glucon-D, Complan and Nycil through acquisitions, is proactively looking for inorganic growth opportunities to support its expansion plans. The company is focusing on innovations for portfolio diversification and expansion to grow its consumer base with increased penetrations, said the latest annual report of Zydus Wellness.

"The company is confident to drive growth and increase the market share of its brands through innovation, leveraging distribution channels and expanding the brand portfolio," said Zydus Wellness.
This will enable the firm to grow its consumer base with increased penetrations.
Moreover, to "support the growth ambitions, the company is proactively looking for bolt-on acquisitions that fit in company's vision and mission," it added.
Advertisement
Zydus Wellness has integrated the business of Heinz, including a portfolio of popular brands Complan, Glucon-D and Nycil, which it had acquired in a Rs 4,595-crore acquisition, the annual report said.
Besides, Zydus Wellness is also expanding into new markets with relevant offerings and building scale in international business by focusing on SAARC (South Asian Association for Regional Cooperation), MEA (Middle-East and Africa) and SEA (South-East Asia) regions.
"The company targets 8-10 per cent revenue contribution from international markets over the next five years," it said.
In FY22, Zydus expanded its international footprints by entering new geographies such as Hong Kong, Lebanon, Zimbabwe, Muscat, Ethiopia and Australia.
"The international business continued to grow at high double digits. The company aims to build scale in international business by focusing on key regions like SAARC, MEA and SEA; entering new geographies and introducing suitable innovations and extensions to address the needs of international markets," the annual report said.
It has also incorporated its wholly-owned subsidiary Zydus Wellness (BD) Pvt Limited in Bangladesh, aimed at serving local consumers at a competitive price,"
In FY22, it had registered a growth of 7.6 percent on its total revenue from operations, which stood at Rs 2,009.10 crore.
"This is despite the fact that there has been a surge in inflation and a rise in geopolitical issues which have impacted consumer sentiments; softening consumer demand," the company said.
Its power brand Glucon-D has maintained its number one position with a market share of 58.5 percent in the Glucose Powder Category.
While Sugar-Free continues to hold its leadership position in sugar with a market share of 95.7 percent.
Similarly, Nycil has maintained its number one position with a market share of 33.7 percent in the prickly heat powder category, the annual report said.
Its e-commerce business had a growth more than 1.5 times in FY22, said Zydus Wellness.
Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Eris Lifesciences receives ANVISA approval at its Ahmedabad campus

India laying foundations to emerge as global MedTech hub, says Shri Amit Agrawal

Mandatory Excipients Disclosure on Drug Labels from March 2026: Health Ministry

CDSCO Cancels Import Licence of Mediderma Salipeel Products

Declare Cancer a Notifiable Disease, Bring Cancer Drugs Under Price Control: Parliamentary Panel

CDSCO Panel Rejects Phase III Trial of QL2107 Injection Proposed by Syneos Health

Piramal Pharma Solutions, NewAmsterdam Pharma open dedicated oral solid dosage form suite at Piramal Sellersville facility

Rs 92 Cr Drug Factory Busted in Bhopal: DRI Arrests 7, Exposes International Mephedrone Syndicate